Keentune

Pharmacy Law & Safety curriculum

12 chapters
·
190 concepts
·
free
Everything the adaptive question bank can teach and test in Pharmacy Law & Safety, from foundations through advanced practice. Work through it in order, or start practising and let the questions find your level.
New here? Read the Pharmacy Law & Safety guide
A free 18-minute primer — the mental model, the mistakes beginners make, and what to practise first.
A. Controlled substances
•
Schedules I–V by abuse potential and accepted medical use, with long-stable examples; C-II security.
•
How a substance is scheduled, rescheduled or descheduled; temporary scheduling and the analogue concept.
•
The three statutory findings (abuse potential, accepted medical use, dependence liability) that place a drug in a schedule.
•
Exempt preparations and behind-the-counter C-V products; why state law often removes the federal option.
•
The Controlled Substances Act: DEA enforces, FDA and HHS supply the medical and scientific evaluation.
•
222/CSOS (C-I/II ordering), 224 (registration), 106 (theft/loss), 41 (destruction).
•
C-II perpetual inventory and ordering/receiving; the biennial inventory.
•
Exact count for Schedule II; estimated count permitted for III–V below a container-size threshold.
•
Initial, biennial and newly-scheduled-drug inventories; taking it at opening or close of business.
•
Reconciling a running C-II log, and what an unexplained variance obliges the pharmacy to do.
•
How opioid treatment and office-based treatment dispensing are structured, at framework level only.
•
Internal diversion patterns: short-fills, voided transactions, waste without a witness, audit-trail gaps.
•
C-II none; C-III/IV ≤5 refills within 6 months; C-V per state; partial-fill concept.
•
C-III–V transferable once (real-time shared-database exception).
•
The pharmacy's duty; red flags: early fills, cash for controls, distance.
•
When federal and state controlled-substance rules differ, the stricter one governs.
•
Substantial cabinet vs dispersal throughout the stock; physical-security factors DEA weighs.
•
Screening and reporting duties around employees with access to controlled substances.
•
Prescription drug monitoring programs: purpose, who queries, and the limits of a query as evidence.
•
Morphine-milligram-equivalent as a comparison tool, naloxone access, and opioid REMS — framed generally, never as dosing advice.
B. Other federal law
•
The Food, Drug and Cosmetic Act: proof of safety before marketing, and the tragedy that produced it.
•
Adding proof of efficacy and adverse-event reporting to the approval bargain.
•
The abbreviated pathway: bioequivalence instead of repeating efficacy trials.
•
Therapeutic-equivalence A/B ratings; generic substitution basics.
•
How shortages are reported and managed, and the substitution questions they raise.
•
How USP–NF standards acquire legal force through the FDCA.
•
REMS programs (iPLEDGE as the flagship); medication guides.
•
IND, the clinical-trial phases, and expanded access at concept level.
•
The legend/OTC line: which products require a prescription and what the caution legend means.
•
Traditional 503A compounding vs 503B outsourcing facilities: who may make what, for whom.
•
The line between compounding for an identified patient and unapproved manufacturing.
•
Biologics licensure, biosimilarity and what "interchangeable" adds.
•
Incentives for small-population diseases, and what "orphan" designates.
•
Sample distribution controls and wholesale-distribution recordkeeping.
•
Why personal importation and non-US-labelled stock are outside the legal supply chain.
•
Track-and-trace concept; pedigree.
•
Class I/II/III severity ladder; who initiates; the technician's role.
•
Pseudoephedrine behind the counter: logbook + ID mechanics (limits live in the vertical guide's registry).
•
Child-resistant caps and the classic exceptions (nitroglycerin SL); patient waiver.
•
OBRA-90 counseling offer; HIPAA/PHI basics in the pharmacy; FDA vs DEA lanes.
•
Fraud, waste and abuse at concept level: what an improper inducement looks like in a pharmacy.
•
Board of pharmacy authority vs federal agencies; technician registration and certification as separate things.
C. Patient safety & quality assurance
•
U, IU, QD/QOD, trailing zero, naked decimal — and the leading-zero rule.
•
Look-alike/sound-alike drugs and tall-man lettering (hydrOXYzine/hydrALAZINE).
•
Insulin, anticoagulants, opioids, concentrated electrolytes.
•
Prescribing/transcribing/dispensing/administration; near-miss; root-cause analysis.
•
FDA MedWatch, VAERS, ISMP (voluntary).
•
Counseling, final verification, and clinical judgment stay with the pharmacist (framed generally).
•
795 (nonsterile), 797 (sterile, beyond-use dating), 800 (hazardous drugs, PPE) at public fact-sheet level.
•
Expiration vs beyond-use date; storage ranges as concepts.
•
Right patient, drug, dose, route, time — and why the framework describes checks, not a guarantee.
•
Trailing zeros, naked decimals, "U", and unit confusion in a written or spoken dose.
•
Recording an allergy with its reaction, and why "intolerance" is not the same field.
•
What prompts a counselling offer, and which questions belong to the pharmacist.
•
Categorising an event by harm reached rather than by how alarming it felt.
•
The sharp end and the blunt end: a design flaw is a cause, not an excuse.
•
Layered defences and why single-layer fixes keep the same event available.
•
Human error, at-risk behaviour and reckless behaviour draw three different responses.
•
Read-back and spell-back for spoken orders; the sound-alike risk verbal orders create.
•
Two identifiers at hand-off; the wrong-patient error that a single identifier permits.
•
Plain-language labels and teach-back as safety controls, not courtesy.
D. Controlled-substance prescriptions & records
•
The elements a controlled prescription must carry before it can be filled.
•
A prescription is only valid if issued for a legitimate medical purpose in the usual course of practice.
•
Why Schedule II normally requires a written or valid electronic prescription.
•
The emergency oral C-II mechanics: quantity limited to the emergency period, written follow-up required.
•
The narrow settings where a fax serves as the original: home infusion, long-term care, hospice.
•
Sequential C-II prescriptions with earliest-fill-date instructions, and what they are not (refills).
•
Partial-fill mechanics for Schedule II and the windows in which the balance may be supplied.
•
Partial fills for III–V inside the refill window, and how the count is documented.
•
What must be recorded on the back of the prescription or in the system each time a control is refilled.
•
What both the transferring and receiving pharmacist must record for a transferred control.
•
Electronic prescribing of controls: identity proofing, two-factor authentication, audit trail.
•
What an agent of the prescriber may communicate, and what only the prescriber may do.
•
The federal caution against transferring a dispensed control to another person.
•
The federal framework for pharmacist dispensing of certain C-V products, and why state law usually narrows it.
•
What the pharmacy must do when a red flag cannot be resolved: document, refuse, do not simply return it.
•
The two-file and three-file prescription filing systems and what each keeps separable.
•
What "readily retrievable" demands of a record, electronic or paper.
E. DEA registration, ordering & disposal
•
Registration is granted per business activity — pharmacy, distributor, researcher — and each authorises different handling.
•
Every principal place of business needs its own registration; no borrowing across sites.
•
The renewal cycle, and what lapsing means for the ability to order or dispense.
•
Employees and agents acting in the usual course of business are not separately registered.
•
Granting and revoking authority to sign order forms; who may hold it.
•
Completing, endorsing and retaining a Schedule I/II order form; handling an unfilled or partial order.
•
Electronic ordering with digital certificates, and how it replaces the paper form.
•
Recording the date and quantity actually received against what was ordered.
•
The federal retention period for controlled-substance records and where they may be kept.
•
When records may be held centrally and the notification that permits it.
•
Reporting a theft or significant loss on the required form, and the separate duty to notify promptly.
•
The factors that make a loss "significant" rather than a routine count variance.
•
Destruction of controlled stock: documentation, witnesses, and non-retrievability.
•
Sending unusable controlled stock to a registered reverse distributor rather than destroying it in-house.
•
Notice of inspection, consent, and the administrative inspection warrant.
F. Labeling, medication guides & packaging
•
What must appear on the container the patient receives.
•
Manufacturer labelling is regulated content; the dispensed label is the pharmacy's added layer.
•
Choosing auxiliary labels that match the drug and the route, not decorating the vial.
•
The standardized OTC panel and the order of its sections.
•
Highlights, indications, dosage, warnings, and where interaction data lives.
•
What earns a boxed warning and what it obliges at the counter.
•
Narrative pregnancy, lactation and reproductive-potential sections replacing letter categories.
•
Products that require a patient insert with every dispensing.
•
When a Medication Guide must be provided and who is responsible for providing it.
•
Assigning a date to the dispensed container that cannot exceed the stock container's.
•
Barcode labelling on drug products and what it enables at the point of dispensing.
•
Tamper-evident requirements for OTC products and what counts as evidence of entry.
•
Labelling requirements when stock is repackaged into unit-dose or a smaller container.
G. Privacy, payer rules & records
•
What makes information protected health information, and the identifiers that carry it.
•
Disclose the least information that accomplishes the purpose — and the requests this rule does not apply to.
•
Uses permitted without authorization, and where that permission stops.
•
Uses that need a signed authorization, such as marketing or most disclosures to an employer.
•
What the notice must say and when it must be offered.
•
Access, amendment, restriction requests and confidential-communication requests.
•
Which disclosures a patient may ask to have listed, and which are excluded.
•
When a vendor becomes a business associate and what the agreement must cover.
•
Administrative, physical and technical safeguards as three separate obligations.
•
Assessing whether an impermissible use is a breach, and the notification duties that follow.
•
Counselling areas, will-call bins and screens: reasonable safeguards against overhearing and over-seeing.
•
Medicare Part D, Medicaid and commercial plans: the pharmacy's role in each, at concept level.
•
What a payer audit looks for, and why the signature log and the profile are the defence.
H. Compounding safety — sterile, nonsterile & hazardous
•
What nonsterile compounding standards govern and the preparation categories they define.
•
What sterile compounding standards govern, and why the air the product meets is the whole subject.
•
Handling standards for hazardous drugs, covering receipt through disposal, for every worker who touches them.
•
Air cleanliness classes as particle counts, and which class each room or device must hold.
•
Laminar-airflow workbench, biological safety cabinet and isolator: what each protects.
•
Buffer and ante rooms, and the segregated compounding area alternative.
•
Positive pressure protects the product; negative pressure protects the worker — hazardous work inverts the sign.
•
Donning order from dirtiest to cleanest, with hand hygiene at the right point in the sequence.
•
Critical sites, no-touch technique, and never blocking first air.
•
Immediate-use and the graded preparation categories, and what each buys in beyond-use time.
•
The factors that set a sterile beyond-use date: sterility assurance, storage, and testing performed.
•
Water content, dosage form and storage as the drivers of a nonsterile beyond-use date.
•
Media-fill and gloved-fingertip testing as proof a person can do the work, not a formality.
•
Viable and nonviable sampling, and what an out-of-limit result obliges.
•
Agents, contact time, sequence and frequency; when a sporicidal agent is required.
•
Chemotherapy-rated gloves, gowns, eye and respiratory protection, and their change intervals.
•
Closed-system drug-transfer devices: what they contain and where they are required rather than optional.
•
Spill-kit contents and the containment-first sequence.
•
Master formulation record vs compounding record: the recipe vs the log of what was actually made.
•
Single-dose vs multi-dose vials, and why an ampoule needs a filter needle.
I. Medication-safety systems & technology
•
What a scan proves (this product) and what it cannot prove (this dose is right for this patient).
•
Independent means genuinely blind; a check performed alongside the first person is one check.
•
Dose-error-reduction libraries, soft and hard limits, and what an override records.
•
Standardised orders and concentrations as a way to remove per-order improvisation.
•
Order entry with decision support removes transcription errors and adds new ones.
•
Too many low-value alerts trains people to dismiss the one that mattered.
•
Physical separation, shelf labelling and sequencing as controls against look-alike picking.
•
Comparing the current list to the new orders at every transition, and who owns the comparison.
•
Root-cause analysis as a structured method: event timeline, contributing factors, system actions.
•
Failure mode and effects analysis: finding the failure before it happens, and ranking by severity and detectability.
•
Plan–do–study–act as the loop that turns a finding into a verified change.
•
What to measure — near misses, interventions, override rates — and the metric that punishes reporting.
•
Override lists, profiled access and the audit trail a cabinet produces.
•
Carousels, counters and robots still need a human verification step, and where that step belongs.
•
Removing or restricting concentrated electrolytes from general stock as a standing control.
J. Infection control & workplace safety
•
When soap and water is required and when an alcohol-based rub suffices.
•
Treating every specimen and every patient contact as potentially infectious.
•
The written exposure-control plan, training, and the offer of hepatitis B vaccination.
•
Engineering controls, no recapping, and point-of-use sharps containers.
•
The immediate steps after a needlestick or splash, and the reporting that must follow.
•
Matching protection to the hazard rather than to habit.
•
Regulated medical, hazardous, controlled and general waste as separate streams.
•
Safety data sheets, container labelling and employee right-to-know.
•
Availability, accessibility and testing of emergency equipment.
•
Why flushing or draining most pharmaceutical waste is not an accepted disposal route.
•
Fire, power loss and evacuation planning for a pharmacy holding temperature-sensitive stock.
•
Cold-chain handling, storage-unit placement and excursion response for vaccines.
K. Prescription processing & verification duties
•
Duplicate therapy, interaction, dose range, allergy and early-refill alerts as distinct signals.
•
Recognising duplication across brand, generic and combination products.
•
What an interaction screen can see and what it cannot (over-the-counter and supplement use).
•
What a complete profile holds, and which missing field blocks a safe fill.
•
Programs where a technician checks another technician's work, and the tasks always excluded.
•
Bin organisation, duplicate-name handling and the identity check at pickup.
•
Which uncollected product may return to stock, its dating, and what may never return.
•
Verifying legibility, completeness and authenticity before data entry begins.
•
Requesting a renewal, and what may be changed on the prescriber's authorisation and what may not.
•
The sequence of the pharmacist's final check against the original prescription.
•
What the signature log records and why an audit begins there.
•
Identity, temperature and controlled-substance constraints on delivery and mail service.
•
Programs that limit which pharmacies may dispense a product, and the enrolment they require.
L. Supply chain, recalls & inventory integrity
•
The transaction information and statement that must accompany product down the chain.
•
Buying only from licensed, authorized partners, and how that status is verified.
•
Identifying, quarantining and investigating suspect product, and clearing or escalating it.
•
What turns a suspect finding into an illegitimate-product determination and the notification it triggers.
•
Verifying a returned package's identifier before it may be resold.
•
Inspecting a shipment on arrival: quantity, condition, temperature indicators, and documentation.
•
Maintaining and documenting the cold chain, and treating an excursion as a quality event.
•
Who must be told when a recall reaches the pharmacy, and how patient notification is decided.
•
Quarantine, quantity reconciliation, return or destruction, and the documentation that closes it.
•
Market withdrawal, medical device safety alert and recall are different actions with different duties.
•
Package, label and pedigree signals that a product is not what it claims to be.
Keentune is not affiliated with or endorsed by the organizations whose documentation informs these maps.
All about Pharmacy Law & Safety practice
Also on your phone
App StoreGoogle Play
All exam, test, and product names and trademarks are the property of their respective owners and are used here for identification and reference only. Keentune is independent study practice — not affiliated with, authorized, or endorsed by any of these organizations.
© 2026 SportaApp LLC